Effects of DMARDs on citrullinated peptide autoantibody levels in RA patients—A longitudinal analysis

Seminars in Arthritis and Rheumatism

Volumn 46, Issue 6, 2017, Pages 709-714

  Wunderlich, Carolin ^a   Oliviera, Isabelle ^a   Figueiredo, Camille P ^a,b   Rech, Juergen ^a   Schett, Georg ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Anti CCP2 antibodies; DMARDs; Immunglobulins; Rheumatoid arthritis

Indexed keywords

ABATACEPT; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; IMMUNOGLOBULIN G; METHOTREXATE; RITUXIMAB; TOCILIZUMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ADAPTIVE IMMUNITY; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; IMMUNOLOGY; MIDDLE AGED;

ABATACEPT; ADULT; AGED; ANTI-CITRULLINATED PROTEIN ANTIBODIES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; METHOTREXATE; MIDDLE AGED; RITUXIMAB; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85009736754     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2016.09.011     Document Type: Article

References (17)

1. McInnes, I.B., Schett, G., The pathogenesis of rheumatoid arthritis. N Engl J Med 365 (2011), 2205–2219.
2. Smolen, J.S., Aletaha, D., Bijlsma, J.W., Breedveld, F.C., Boumpas, D., Burmester, G., et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69 (2010), 631–637.
3. Aga, A.B., Lie, E., Uhlig, T., Olsen, I. Christoffer, Wierod, A., Kalstad, S., et al. Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000–2010. Ann Rheum Dis 74 (2015), 381–388.
4. Barra, L., Pope, J., Bessette, L., Haraoui, B., Bykerk, V., Lack of seroconversion of rheumatoid factor and anti-cyclic citrullinated peptide in patients with early inflammatory arthritis: a systematic literature review. Rheumatology (Oxford) 50 (2011), 311–316.
5. Cuchacovich, M., Catalan, D., Wainstein, E., Gatica, H., Soto, L., Aravena, O., et al. Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis. Clin Exp Rheumatol 26 (2008), 1067–1073.
6. Harre, U., Georgess, D., Bang, H., Bozec, A., Axmann, R., Ossipova, E., et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullineated vimentin. J Clin Invest 122 (2012), 1791–1802.
7. Harre, U., Lang, S., Pfeifle, R., Rombouts, Y., Frühbeißer, S., Amara, K., et al. Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss. Nat Commun, 31, 2015, 6651.
8. Wigerblad, G., Bas, D.B., Fernades-Cerqueira, C., Krishnamurthy, A., Nandakumar, K.S., Rogoz, K., et al. Autoantibodies to citrullinated proteins induce joint pain independent of inflammation via a chemokine-dependent mechanism. Ann Rheum Dis 75 (2016), 730–738.
9. Reynisdottir, G., Karimi, R., Joshua, V., Olsen, H., Hensvold, A.H., Harju, A., et al. Structural changes and antibody enrichment in the lungs are early features of anti-citrullinated protein antibody-positive rheumatoid arthritis. Arthritis Rheumatol 66 (2014), 31–39.
10. Ytterberg, A.J., Joshua, V., Reynisdottir, G., Tarasova, N.K., Rutishauser, D., Ossipova, E., et al. Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: identification and validation. Ann Rheum Dis 74 (2015), 1772–1777.
11. Haschka, J., Englbrecht, M., Hueber, A.J., Manger, B., Kleyer, A., Reiser, M., et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping anti-rheumatic therapy—interim results from the prospective randomized controlled RETRO study. Ann Rheum Dis 74 (2015), 1772–1777.
12. Eisenberg, R., Update on rituximab. Ann Rheum Dis, 64(Suppl. 4), 2005 iv55-7.
13. Buch, M.H., Smolen, J.S., Betteridge, N., Breedveld, F.C., Burmester, G., Dörner, T., et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 70 (2011), 909–920.
14. Moreland, L., Bate, G., Kirkpatrick, P., Abatacept. Nat Rev Drug Discov 5 (2006), 185–186.
15. Iwata, S., Nakayamada, S., Fukuyo, S., Kubo, S., Yunoue, N., Wang, S.P., et al. Activation of Syk in peripheral blood B cells in patients with rheumatoid arthritis: a potential target for abatacept therapy. Arthritis Rheumatol 67 (2015), 63–73.
16. Connolly, S., Maldonado, M., Schiff, M., Weinblatt, M., Fleischmann, R., Robinson, W., et al. Modulation of ACPA fine specifcity in patients with RA treated with either abatacept or adalimumab in the AMPLE study. Ann Rheum Dis, 73(Suppl. 2), 2014, S395.
17. Iannone, F., Tampoia, M., Giannini, M., Lopalco, G., Cantarini, L., Villalta, C.D., et al. Changes in anti-cyclic citrullinated peptide antibodies and rheumatoid factor isotypes serum levels in patients with rheumatoid arthritis following treatment with different biological drugs. Clin Exp Rheum 34 (2016), 424–429.